The therapeutic vulnerability of PDA patients could be predicted by the profile of the KRAS/PI3K genome, suggesting that targeting PI3K in KRAS mutations may be a novel strategy for the treatment of CRC. This evidence concerns the gene PIK3CB and colorectal carcinoma.